Global Ustekinumab Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.
LPI (LP Information)' newest research report, the “Ustekinumab Industry Forecast” looks at past sales and reviews total world Ustekinumab sales in 2022, providing a comprehensive analysis by region and market sector of projected Ustekinumab sales for 2023 through 2029. With Ustekinumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ustekinumab industry.
This Insight Report provides a comprehensive analysis of the global Ustekinumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ustekinumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Ustekinumab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ustekinumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ustekinumab.
The global Ustekinumab market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Ustekinumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Ustekinumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Ustekinumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Ustekinumab players cover Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi Tanabe, Stada, EPIRUS BioPharma, Formycon and NeuClone, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Ustekinumab market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Ustekinumab market?
What factors are driving Ustekinumab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ustekinumab market opportunities vary by end market size?
How does Ustekinumab break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.
LPI (LP Information)' newest research report, the “Ustekinumab Industry Forecast” looks at past sales and reviews total world Ustekinumab sales in 2022, providing a comprehensive analysis by region and market sector of projected Ustekinumab sales for 2023 through 2029. With Ustekinumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ustekinumab industry.
This Insight Report provides a comprehensive analysis of the global Ustekinumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ustekinumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Ustekinumab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ustekinumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ustekinumab.
The global Ustekinumab market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Ustekinumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Ustekinumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Ustekinumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Ustekinumab players cover Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi Tanabe, Stada, EPIRUS BioPharma, Formycon and NeuClone, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Ustekinumab market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Intravenous
- Subcutaneous
- Arthritis
- Colitis
- Lupus Erythematosus
- Myositis Multiplex With Palmoplantar Pustulosis
- Cirrhosis Of The Liver
- Sarcoidosis
- Diabetes
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Meiji
- Johnson & Johnson
- Alvotech
- Fuji Pharma
- Mitsubishi Tanabe
- Stada
- EPIRUS BioPharma
- Formycon
- NeuClone
- Outlook Therapeutics
- Harvest Moon Pharma
- BioXpress
What is the 10-year outlook for the global Ustekinumab market?
What factors are driving Ustekinumab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ustekinumab market opportunities vary by end market size?
How does Ustekinumab break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ustekinumab Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Ustekinumab by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Ustekinumab by Country/Region, 2018, 2022 & 2029
2.2 Ustekinumab Segment by Type
2.2.1 Intravenous
2.2.2 Subcutaneous
2.3 Ustekinumab Sales by Type
2.3.1 Global Ustekinumab Sales Market Share by Type (2018-2023)
2.3.2 Global Ustekinumab Revenue and Market Share by Type (2018-2023)
2.3.3 Global Ustekinumab Sale Price by Type (2018-2023)
2.4 Ustekinumab Segment by Application
2.4.1 Arthritis
2.4.2 Colitis
2.4.3 Lupus Erythematosus
2.4.4 Myositis Multiplex With Palmoplantar Pustulosis
2.4.5 Cirrhosis Of The Liver
2.4.6 Sarcoidosis
2.4.7 Diabetes
2.4.8 Other
2.5 Ustekinumab Sales by Application
2.5.1 Global Ustekinumab Sale Market Share by Application (2018-2023)
2.5.2 Global Ustekinumab Revenue and Market Share by Application (2018-2023)
2.5.3 Global Ustekinumab Sale Price by Application (2018-2023)
3 GLOBAL USTEKINUMAB BY COMPANY
3.1 Global Ustekinumab Breakdown Data by Company
3.1.1 Global Ustekinumab Annual Sales by Company (2018-2023)
3.1.2 Global Ustekinumab Sales Market Share by Company (2018-2023)
3.2 Global Ustekinumab Annual Revenue by Company (2018-2023)
3.2.1 Global Ustekinumab Revenue by Company (2018-2023)
3.2.2 Global Ustekinumab Revenue Market Share by Company (2018-2023)
3.3 Global Ustekinumab Sale Price by Company
3.4 Key Manufacturers Ustekinumab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ustekinumab Product Location Distribution
3.4.2 Players Ustekinumab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR USTEKINUMAB BY GEOGRAPHIC REGION
4.1 World Historic Ustekinumab Market Size by Geographic Region (2018-2023)
4.1.1 Global Ustekinumab Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Ustekinumab Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Ustekinumab Market Size by Country/Region (2018-2023)
4.2.1 Global Ustekinumab Annual Sales by Country/Region (2018-2023)
4.2.2 Global Ustekinumab Annual Revenue by Country/Region (2018-2023)
4.3 Americas Ustekinumab Sales Growth
4.4 APAC Ustekinumab Sales Growth
4.5 Europe Ustekinumab Sales Growth
4.6 Middle East & Africa Ustekinumab Sales Growth
5 AMERICAS
5.1 Americas Ustekinumab Sales by Country
5.1.1 Americas Ustekinumab Sales by Country (2018-2023)
5.1.2 Americas Ustekinumab Revenue by Country (2018-2023)
5.2 Americas Ustekinumab Sales by Type
5.3 Americas Ustekinumab Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ustekinumab Sales by Region
6.1.1 APAC Ustekinumab Sales by Region (2018-2023)
6.1.2 APAC Ustekinumab Revenue by Region (2018-2023)
6.2 APAC Ustekinumab Sales by Type
6.3 APAC Ustekinumab Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ustekinumab by Country
7.1.1 Europe Ustekinumab Sales by Country (2018-2023)
7.1.2 Europe Ustekinumab Revenue by Country (2018-2023)
7.2 Europe Ustekinumab Sales by Type
7.3 Europe Ustekinumab Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ustekinumab by Country
8.1.1 Middle East & Africa Ustekinumab Sales by Country (2018-2023)
8.1.2 Middle East & Africa Ustekinumab Revenue by Country (2018-2023)
8.2 Middle East & Africa Ustekinumab Sales by Type
8.3 Middle East & Africa Ustekinumab Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ustekinumab
10.3 Manufacturing Process Analysis of Ustekinumab
10.4 Industry Chain Structure of Ustekinumab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ustekinumab Distributors
11.3 Ustekinumab Customer
12 WORLD FORECAST REVIEW FOR USTEKINUMAB BY GEOGRAPHIC REGION
12.1 Global Ustekinumab Market Size Forecast by Region
12.1.1 Global Ustekinumab Forecast by Region (2024-2029)
12.1.2 Global Ustekinumab Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ustekinumab Forecast by Type
12.7 Global Ustekinumab Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Meiji
13.1.1 Meiji Company Information
13.1.2 Meiji Ustekinumab Product Portfolios and Specifications
13.1.3 Meiji Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Meiji Main Business Overview
13.1.5 Meiji Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Ustekinumab Product Portfolios and Specifications
13.2.3 Johnson & Johnson Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Alvotech
13.3.1 Alvotech Company Information
13.3.2 Alvotech Ustekinumab Product Portfolios and Specifications
13.3.3 Alvotech Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Alvotech Main Business Overview
13.3.5 Alvotech Latest Developments
13.4 Fuji Pharma
13.4.1 Fuji Pharma Company Information
13.4.2 Fuji Pharma Ustekinumab Product Portfolios and Specifications
13.4.3 Fuji Pharma Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Fuji Pharma Main Business Overview
13.4.5 Fuji Pharma Latest Developments
13.5 Mitsubishi Tanabe
13.5.1 Mitsubishi Tanabe Company Information
13.5.2 Mitsubishi Tanabe Ustekinumab Product Portfolios and Specifications
13.5.3 Mitsubishi Tanabe Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Mitsubishi Tanabe Main Business Overview
13.5.5 Mitsubishi Tanabe Latest Developments
13.6 Stada
13.6.1 Stada Company Information
13.6.2 Stada Ustekinumab Product Portfolios and Specifications
13.6.3 Stada Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Stada Main Business Overview
13.6.5 Stada Latest Developments
13.7 EPIRUS BioPharma
13.7.1 EPIRUS BioPharma Company Information
13.7.2 EPIRUS BioPharma Ustekinumab Product Portfolios and Specifications
13.7.3 EPIRUS BioPharma Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 EPIRUS BioPharma Main Business Overview
13.7.5 EPIRUS BioPharma Latest Developments
13.8 Formycon
13.8.1 Formycon Company Information
13.8.2 Formycon Ustekinumab Product Portfolios and Specifications
13.8.3 Formycon Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Formycon Main Business Overview
13.8.5 Formycon Latest Developments
13.9 NeuClone
13.9.1 NeuClone Company Information
13.9.2 NeuClone Ustekinumab Product Portfolios and Specifications
13.9.3 NeuClone Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 NeuClone Main Business Overview
13.9.5 NeuClone Latest Developments
13.10 Outlook Therapeutics
13.10.1 Outlook Therapeutics Company Information
13.10.2 Outlook Therapeutics Ustekinumab Product Portfolios and Specifications
13.10.3 Outlook Therapeutics Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Outlook Therapeutics Main Business Overview
13.10.5 Outlook Therapeutics Latest Developments
13.11 Harvest Moon Pharma
13.11.1 Harvest Moon Pharma Company Information
13.11.2 Harvest Moon Pharma Ustekinumab Product Portfolios and Specifications
13.11.3 Harvest Moon Pharma Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Harvest Moon Pharma Main Business Overview
13.11.5 Harvest Moon Pharma Latest Developments
13.12 BioXpress
13.12.1 BioXpress Company Information
13.12.2 BioXpress Ustekinumab Product Portfolios and Specifications
13.12.3 BioXpress Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 BioXpress Main Business Overview
13.12.5 BioXpress Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ustekinumab Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Ustekinumab by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Ustekinumab by Country/Region, 2018, 2022 & 2029
2.2 Ustekinumab Segment by Type
2.2.1 Intravenous
2.2.2 Subcutaneous
2.3 Ustekinumab Sales by Type
2.3.1 Global Ustekinumab Sales Market Share by Type (2018-2023)
2.3.2 Global Ustekinumab Revenue and Market Share by Type (2018-2023)
2.3.3 Global Ustekinumab Sale Price by Type (2018-2023)
2.4 Ustekinumab Segment by Application
2.4.1 Arthritis
2.4.2 Colitis
2.4.3 Lupus Erythematosus
2.4.4 Myositis Multiplex With Palmoplantar Pustulosis
2.4.5 Cirrhosis Of The Liver
2.4.6 Sarcoidosis
2.4.7 Diabetes
2.4.8 Other
2.5 Ustekinumab Sales by Application
2.5.1 Global Ustekinumab Sale Market Share by Application (2018-2023)
2.5.2 Global Ustekinumab Revenue and Market Share by Application (2018-2023)
2.5.3 Global Ustekinumab Sale Price by Application (2018-2023)
3 GLOBAL USTEKINUMAB BY COMPANY
3.1 Global Ustekinumab Breakdown Data by Company
3.1.1 Global Ustekinumab Annual Sales by Company (2018-2023)
3.1.2 Global Ustekinumab Sales Market Share by Company (2018-2023)
3.2 Global Ustekinumab Annual Revenue by Company (2018-2023)
3.2.1 Global Ustekinumab Revenue by Company (2018-2023)
3.2.2 Global Ustekinumab Revenue Market Share by Company (2018-2023)
3.3 Global Ustekinumab Sale Price by Company
3.4 Key Manufacturers Ustekinumab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ustekinumab Product Location Distribution
3.4.2 Players Ustekinumab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR USTEKINUMAB BY GEOGRAPHIC REGION
4.1 World Historic Ustekinumab Market Size by Geographic Region (2018-2023)
4.1.1 Global Ustekinumab Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Ustekinumab Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Ustekinumab Market Size by Country/Region (2018-2023)
4.2.1 Global Ustekinumab Annual Sales by Country/Region (2018-2023)
4.2.2 Global Ustekinumab Annual Revenue by Country/Region (2018-2023)
4.3 Americas Ustekinumab Sales Growth
4.4 APAC Ustekinumab Sales Growth
4.5 Europe Ustekinumab Sales Growth
4.6 Middle East & Africa Ustekinumab Sales Growth
5 AMERICAS
5.1 Americas Ustekinumab Sales by Country
5.1.1 Americas Ustekinumab Sales by Country (2018-2023)
5.1.2 Americas Ustekinumab Revenue by Country (2018-2023)
5.2 Americas Ustekinumab Sales by Type
5.3 Americas Ustekinumab Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ustekinumab Sales by Region
6.1.1 APAC Ustekinumab Sales by Region (2018-2023)
6.1.2 APAC Ustekinumab Revenue by Region (2018-2023)
6.2 APAC Ustekinumab Sales by Type
6.3 APAC Ustekinumab Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ustekinumab by Country
7.1.1 Europe Ustekinumab Sales by Country (2018-2023)
7.1.2 Europe Ustekinumab Revenue by Country (2018-2023)
7.2 Europe Ustekinumab Sales by Type
7.3 Europe Ustekinumab Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ustekinumab by Country
8.1.1 Middle East & Africa Ustekinumab Sales by Country (2018-2023)
8.1.2 Middle East & Africa Ustekinumab Revenue by Country (2018-2023)
8.2 Middle East & Africa Ustekinumab Sales by Type
8.3 Middle East & Africa Ustekinumab Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ustekinumab
10.3 Manufacturing Process Analysis of Ustekinumab
10.4 Industry Chain Structure of Ustekinumab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ustekinumab Distributors
11.3 Ustekinumab Customer
12 WORLD FORECAST REVIEW FOR USTEKINUMAB BY GEOGRAPHIC REGION
12.1 Global Ustekinumab Market Size Forecast by Region
12.1.1 Global Ustekinumab Forecast by Region (2024-2029)
12.1.2 Global Ustekinumab Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ustekinumab Forecast by Type
12.7 Global Ustekinumab Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Meiji
13.1.1 Meiji Company Information
13.1.2 Meiji Ustekinumab Product Portfolios and Specifications
13.1.3 Meiji Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Meiji Main Business Overview
13.1.5 Meiji Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Ustekinumab Product Portfolios and Specifications
13.2.3 Johnson & Johnson Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Alvotech
13.3.1 Alvotech Company Information
13.3.2 Alvotech Ustekinumab Product Portfolios and Specifications
13.3.3 Alvotech Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Alvotech Main Business Overview
13.3.5 Alvotech Latest Developments
13.4 Fuji Pharma
13.4.1 Fuji Pharma Company Information
13.4.2 Fuji Pharma Ustekinumab Product Portfolios and Specifications
13.4.3 Fuji Pharma Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Fuji Pharma Main Business Overview
13.4.5 Fuji Pharma Latest Developments
13.5 Mitsubishi Tanabe
13.5.1 Mitsubishi Tanabe Company Information
13.5.2 Mitsubishi Tanabe Ustekinumab Product Portfolios and Specifications
13.5.3 Mitsubishi Tanabe Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Mitsubishi Tanabe Main Business Overview
13.5.5 Mitsubishi Tanabe Latest Developments
13.6 Stada
13.6.1 Stada Company Information
13.6.2 Stada Ustekinumab Product Portfolios and Specifications
13.6.3 Stada Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Stada Main Business Overview
13.6.5 Stada Latest Developments
13.7 EPIRUS BioPharma
13.7.1 EPIRUS BioPharma Company Information
13.7.2 EPIRUS BioPharma Ustekinumab Product Portfolios and Specifications
13.7.3 EPIRUS BioPharma Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 EPIRUS BioPharma Main Business Overview
13.7.5 EPIRUS BioPharma Latest Developments
13.8 Formycon
13.8.1 Formycon Company Information
13.8.2 Formycon Ustekinumab Product Portfolios and Specifications
13.8.3 Formycon Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Formycon Main Business Overview
13.8.5 Formycon Latest Developments
13.9 NeuClone
13.9.1 NeuClone Company Information
13.9.2 NeuClone Ustekinumab Product Portfolios and Specifications
13.9.3 NeuClone Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 NeuClone Main Business Overview
13.9.5 NeuClone Latest Developments
13.10 Outlook Therapeutics
13.10.1 Outlook Therapeutics Company Information
13.10.2 Outlook Therapeutics Ustekinumab Product Portfolios and Specifications
13.10.3 Outlook Therapeutics Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Outlook Therapeutics Main Business Overview
13.10.5 Outlook Therapeutics Latest Developments
13.11 Harvest Moon Pharma
13.11.1 Harvest Moon Pharma Company Information
13.11.2 Harvest Moon Pharma Ustekinumab Product Portfolios and Specifications
13.11.3 Harvest Moon Pharma Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Harvest Moon Pharma Main Business Overview
13.11.5 Harvest Moon Pharma Latest Developments
13.12 BioXpress
13.12.1 BioXpress Company Information
13.12.2 BioXpress Ustekinumab Product Portfolios and Specifications
13.12.3 BioXpress Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 BioXpress Main Business Overview
13.12.5 BioXpress Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Ustekinumab Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Ustekinumab Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Intravenous
Table 4. Major Players of Subcutaneous
Table 5. Global Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 6. Global Ustekinumab Sales Market Share by Type (2018-2023)
Table 7. Global Ustekinumab Revenue by Type (2018-2023) & ($ million)
Table 8. Global Ustekinumab Revenue Market Share by Type (2018-2023)
Table 9. Global Ustekinumab Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 11. Global Ustekinumab Sales Market Share by Application (2018-2023)
Table 12. Global Ustekinumab Revenue by Application (2018-2023)
Table 13. Global Ustekinumab Revenue Market Share by Application (2018-2023)
Table 14. Global Ustekinumab Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Ustekinumab Sales by Company (2018-2023) & (K Units)
Table 16. Global Ustekinumab Sales Market Share by Company (2018-2023)
Table 17. Global Ustekinumab Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Ustekinumab Revenue Market Share by Company (2018-2023)
Table 19. Global Ustekinumab Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Ustekinumab Producing Area Distribution and Sales Area
Table 21. Players Ustekinumab Products Offered
Table 22. Ustekinumab Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Ustekinumab Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Ustekinumab Sales Market Share Geographic Region (2018-2023)
Table 27. Global Ustekinumab Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Ustekinumab Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Ustekinumab Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Ustekinumab Sales Market Share by Country/Region (2018-2023)
Table 31. Global Ustekinumab Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Ustekinumab Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Ustekinumab Sales by Country (2018-2023) & (K Units)
Table 34. Americas Ustekinumab Sales Market Share by Country (2018-2023)
Table 35. Americas Ustekinumab Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Ustekinumab Revenue Market Share by Country (2018-2023)
Table 37. Americas Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 38. Americas Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 39. APAC Ustekinumab Sales by Region (2018-2023) & (K Units)
Table 40. APAC Ustekinumab Sales Market Share by Region (2018-2023)
Table 41. APAC Ustekinumab Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Ustekinumab Revenue Market Share by Region (2018-2023)
Table 43. APAC Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 44. APAC Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 45. Europe Ustekinumab Sales by Country (2018-2023) & (K Units)
Table 46. Europe Ustekinumab Sales Market Share by Country (2018-2023)
Table 47. Europe Ustekinumab Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Ustekinumab Revenue Market Share by Country (2018-2023)
Table 49. Europe Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 50. Europe Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Ustekinumab Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Ustekinumab Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Ustekinumab Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Ustekinumab Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Ustekinumab
Table 58. Key Market Challenges & Risks of Ustekinumab
Table 59. Key Industry Trends of Ustekinumab
Table 60. Ustekinumab Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Ustekinumab Distributors List
Table 63. Ustekinumab Customer List
Table 64. Global Ustekinumab Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Ustekinumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Ustekinumab Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Ustekinumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Ustekinumab Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Ustekinumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Ustekinumab Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Ustekinumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Ustekinumab Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Ustekinumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Ustekinumab Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Ustekinumab Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Ustekinumab Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Ustekinumab Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Meiji Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 79. Meiji Ustekinumab Product Portfolios and Specifications
Table 80. Meiji Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Meiji Main Business
Table 82. Meiji Latest Developments
Table 83. Johnson & Johnson Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 84. Johnson & Johnson Ustekinumab Product Portfolios and Specifications
Table 85. Johnson & Johnson Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Johnson & Johnson Main Business
Table 87. Johnson & Johnson Latest Developments
Table 88. Alvotech Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 89. Alvotech Ustekinumab Product Portfolios and Specifications
Table 90. Alvotech Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Alvotech Main Business
Table 92. Alvotech Latest Developments
Table 93. Fuji Pharma Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 94. Fuji Pharma Ustekinumab Product Portfolios and Specifications
Table 95. Fuji Pharma Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Fuji Pharma Main Business
Table 97. Fuji Pharma Latest Developments
Table 98. Mitsubishi Tanabe Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 99. Mitsubishi Tanabe Ustekinumab Product Portfolios and Specifications
Table 100. Mitsubishi Tanabe Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Mitsubishi Tanabe Main Business
Table 102. Mitsubishi Tanabe Latest Developments
Table 103. Stada Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 104. Stada Ustekinumab Product Portfolios and Specifications
Table 105. Stada Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Stada Main Business
Table 107. Stada Latest Developments
Table 108. EPIRUS BioPharma Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 109. EPIRUS BioPharma Ustekinumab Product Portfolios and Specifications
Table 110. EPIRUS BioPharma Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. EPIRUS BioPharma Main Business
Table 112. EPIRUS BioPharma Latest Developments
Table 113. Formycon Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 114. Formycon Ustekinumab Product Portfolios and Specifications
Table 115. Formycon Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Formycon Main Business
Table 117. Formycon Latest Developments
Table 118. NeuClone Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 119. NeuClone Ustekinumab Product Portfolios and Specifications
Table 120. NeuClone Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. NeuClone Main Business
Table 122. NeuClone Latest Developments
Table 123. Outlook Therapeutics Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 124. Outlook Therapeutics Ustekinumab Product Portfolios and Specifications
Table 125. Outlook Therapeutics Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Outlook Therapeutics Main Business
Table 127. Outlook Therapeutics Latest Developments
Table 128. Harvest Moon Pharma Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 129. Harvest Moon Pharma Ustekinumab Product Portfolios and Specifications
Table 130. Harvest Moon Pharma Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. Harvest Moon Pharma Main Business
Table 132. Harvest Moon Pharma Latest Developments
Table 133. BioXpress Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 134. BioXpress Ustekinumab Product Portfolios and Specifications
Table 135. BioXpress Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. BioXpress Main Business
Table 137. BioXpress Latest Developments
Table 1. Ustekinumab Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Ustekinumab Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Intravenous
Table 4. Major Players of Subcutaneous
Table 5. Global Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 6. Global Ustekinumab Sales Market Share by Type (2018-2023)
Table 7. Global Ustekinumab Revenue by Type (2018-2023) & ($ million)
Table 8. Global Ustekinumab Revenue Market Share by Type (2018-2023)
Table 9. Global Ustekinumab Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 11. Global Ustekinumab Sales Market Share by Application (2018-2023)
Table 12. Global Ustekinumab Revenue by Application (2018-2023)
Table 13. Global Ustekinumab Revenue Market Share by Application (2018-2023)
Table 14. Global Ustekinumab Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Ustekinumab Sales by Company (2018-2023) & (K Units)
Table 16. Global Ustekinumab Sales Market Share by Company (2018-2023)
Table 17. Global Ustekinumab Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Ustekinumab Revenue Market Share by Company (2018-2023)
Table 19. Global Ustekinumab Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Ustekinumab Producing Area Distribution and Sales Area
Table 21. Players Ustekinumab Products Offered
Table 22. Ustekinumab Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Ustekinumab Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Ustekinumab Sales Market Share Geographic Region (2018-2023)
Table 27. Global Ustekinumab Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Ustekinumab Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Ustekinumab Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Ustekinumab Sales Market Share by Country/Region (2018-2023)
Table 31. Global Ustekinumab Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Ustekinumab Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Ustekinumab Sales by Country (2018-2023) & (K Units)
Table 34. Americas Ustekinumab Sales Market Share by Country (2018-2023)
Table 35. Americas Ustekinumab Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Ustekinumab Revenue Market Share by Country (2018-2023)
Table 37. Americas Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 38. Americas Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 39. APAC Ustekinumab Sales by Region (2018-2023) & (K Units)
Table 40. APAC Ustekinumab Sales Market Share by Region (2018-2023)
Table 41. APAC Ustekinumab Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Ustekinumab Revenue Market Share by Region (2018-2023)
Table 43. APAC Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 44. APAC Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 45. Europe Ustekinumab Sales by Country (2018-2023) & (K Units)
Table 46. Europe Ustekinumab Sales Market Share by Country (2018-2023)
Table 47. Europe Ustekinumab Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Ustekinumab Revenue Market Share by Country (2018-2023)
Table 49. Europe Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 50. Europe Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Ustekinumab Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Ustekinumab Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Ustekinumab Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Ustekinumab Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Ustekinumab
Table 58. Key Market Challenges & Risks of Ustekinumab
Table 59. Key Industry Trends of Ustekinumab
Table 60. Ustekinumab Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Ustekinumab Distributors List
Table 63. Ustekinumab Customer List
Table 64. Global Ustekinumab Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Ustekinumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Ustekinumab Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Ustekinumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Ustekinumab Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Ustekinumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Ustekinumab Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Ustekinumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Ustekinumab Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Ustekinumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Ustekinumab Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Ustekinumab Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Ustekinumab Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Ustekinumab Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Meiji Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 79. Meiji Ustekinumab Product Portfolios and Specifications
Table 80. Meiji Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Meiji Main Business
Table 82. Meiji Latest Developments
Table 83. Johnson & Johnson Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 84. Johnson & Johnson Ustekinumab Product Portfolios and Specifications
Table 85. Johnson & Johnson Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Johnson & Johnson Main Business
Table 87. Johnson & Johnson Latest Developments
Table 88. Alvotech Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 89. Alvotech Ustekinumab Product Portfolios and Specifications
Table 90. Alvotech Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Alvotech Main Business
Table 92. Alvotech Latest Developments
Table 93. Fuji Pharma Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 94. Fuji Pharma Ustekinumab Product Portfolios and Specifications
Table 95. Fuji Pharma Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Fuji Pharma Main Business
Table 97. Fuji Pharma Latest Developments
Table 98. Mitsubishi Tanabe Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 99. Mitsubishi Tanabe Ustekinumab Product Portfolios and Specifications
Table 100. Mitsubishi Tanabe Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Mitsubishi Tanabe Main Business
Table 102. Mitsubishi Tanabe Latest Developments
Table 103. Stada Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 104. Stada Ustekinumab Product Portfolios and Specifications
Table 105. Stada Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Stada Main Business
Table 107. Stada Latest Developments
Table 108. EPIRUS BioPharma Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 109. EPIRUS BioPharma Ustekinumab Product Portfolios and Specifications
Table 110. EPIRUS BioPharma Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. EPIRUS BioPharma Main Business
Table 112. EPIRUS BioPharma Latest Developments
Table 113. Formycon Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 114. Formycon Ustekinumab Product Portfolios and Specifications
Table 115. Formycon Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Formycon Main Business
Table 117. Formycon Latest Developments
Table 118. NeuClone Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 119. NeuClone Ustekinumab Product Portfolios and Specifications
Table 120. NeuClone Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. NeuClone Main Business
Table 122. NeuClone Latest Developments
Table 123. Outlook Therapeutics Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 124. Outlook Therapeutics Ustekinumab Product Portfolios and Specifications
Table 125. Outlook Therapeutics Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Outlook Therapeutics Main Business
Table 127. Outlook Therapeutics Latest Developments
Table 128. Harvest Moon Pharma Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 129. Harvest Moon Pharma Ustekinumab Product Portfolios and Specifications
Table 130. Harvest Moon Pharma Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. Harvest Moon Pharma Main Business
Table 132. Harvest Moon Pharma Latest Developments
Table 133. BioXpress Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors
Table 134. BioXpress Ustekinumab Product Portfolios and Specifications
Table 135. BioXpress Ustekinumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. BioXpress Main Business
Table 137. BioXpress Latest Developments
LIST OF FIGURES
Figure 1. Picture of Ustekinumab
Figure 2. Ustekinumab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ustekinumab Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Ustekinumab Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Ustekinumab Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Intravenous
Figure 10. Product Picture of Subcutaneous
Figure 11. Global Ustekinumab Sales Market Share by Type in 2022
Figure 12. Global Ustekinumab Revenue Market Share by Type (2018-2023)
Figure 13. Ustekinumab Consumed in Arthritis
Figure 14. Global Ustekinumab Market: Arthritis (2018-2023) & (K Units)
Figure 15. Ustekinumab Consumed in Colitis
Figure 16. Global Ustekinumab Market: Colitis (2018-2023) & (K Units)
Figure 17. Ustekinumab Consumed in Lupus Erythematosus
Figure 18. Global Ustekinumab Market: Lupus Erythematosus (2018-2023) & (K Units)
Figure 19. Ustekinumab Consumed in Myositis Multiplex With Palmoplantar Pustulosis
Figure 20. Global Ustekinumab Market: Myositis Multiplex With Palmoplantar Pustulosis (2018-2023) & (K Units)
Figure 21. Ustekinumab Consumed in Cirrhosis Of The Liver
Figure 22. Global Ustekinumab Market: Cirrhosis Of The Liver (2018-2023) & (K Units)
Figure 23. Ustekinumab Consumed in Sarcoidosis
Figure 24. Global Ustekinumab Market: Sarcoidosis (2018-2023) & (K Units)
Figure 25. Ustekinumab Consumed in Diabetes
Figure 26. Global Ustekinumab Market: Diabetes (2018-2023) & (K Units)
Figure 27. Ustekinumab Consumed in Other
Figure 28. Global Ustekinumab Market: Other (2018-2023) & (K Units)
Figure 29. Global Ustekinumab Sales Market Share by Application (2022)
Figure 30. Global Ustekinumab Revenue Market Share by Application in 2022
Figure 31. Ustekinumab Sales Market by Company in 2022 (K Units)
Figure 32. Global Ustekinumab Sales Market Share by Company in 2022
Figure 33. Ustekinumab Revenue Market by Company in 2022 ($ Million)
Figure 34. Global Ustekinumab Revenue Market Share by Company in 2022
Figure 35. Global Ustekinumab Sales Market Share by Geographic Region (2018-2023)
Figure 36. Global Ustekinumab Revenue Market Share by Geographic Region in 2022
Figure 37. Americas Ustekinumab Sales 2018-2023 (K Units)
Figure 38. Americas Ustekinumab Revenue 2018-2023 ($ Millions)
Figure 39. APAC Ustekinumab Sales 2018-2023 (K Units)
Figure 40. APAC Ustekinumab Revenue 2018-2023 ($ Millions)
Figure 41. Europe Ustekinumab Sales 2018-2023 (K Units)
Figure 42. Europe Ustekinumab Revenue 2018-2023 ($ Millions)
Figure 43. Middle East & Africa Ustekinumab Sales 2018-2023 (K Units)
Figure 44. Middle East & Africa Ustekinumab Revenue 2018-2023 ($ Millions)
Figure 45. Americas Ustekinumab Sales Market Share by Country in 2022
Figure 46. Americas Ustekinumab Revenue Market Share by Country in 2022
Figure 47. Americas Ustekinumab Sales Market Share by Type (2018-2023)
Figure 48. Americas Ustekinumab Sales Market Share by Application (2018-2023)
Figure 49. United States Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 50. Canada Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 51. Mexico Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 52. Brazil Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 53. APAC Ustekinumab Sales Market Share by Region in 2022
Figure 54. APAC Ustekinumab Revenue Market Share by Regions in 2022
Figure 55. APAC Ustekinumab Sales Market Share by Type (2018-2023)
Figure 56. APAC Ustekinumab Sales Market Share by Application (2018-2023)
Figure 57. China Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 58. Japan Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 59. South Korea Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 60. Southeast Asia Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 61. India Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 62. Australia Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 63. China Taiwan Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 64. Europe Ustekinumab Sales Market Share by Country in 2022
Figure 65. Europe Ustekinumab Revenue Market Share by Country in 2022
Figure 66. Europe Ustekinumab Sales Market Share by Type (2018-2023)
Figure 67. Europe Ustekinumab Sales Market Share by Application (2018-2023)
Figure 68. Germany Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 69. France Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 70. UK Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 71. Italy Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 72. Russia Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 73. Middle East & Africa Ustekinumab Sales Market Share by Country in 2022
Figure 74. Middle East & Africa Ustekinumab Revenue Market Share by Country in 2022
Figure 75. Middle East & Africa Ustekinumab Sales Market Share by Type (2018-2023)
Figure 76. Middle East & Africa Ustekinumab Sales Market Share by Application (2018-2023)
Figure 77. Egypt Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 78. South Africa Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 79. Israel Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 80. Turkey Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 81. GCC Country Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 82. Manufacturing Cost Structure Analysis of Ustekinumab in 2022
Figure 83. Manufacturing Process Analysis of Ustekinumab
Figure 84. Industry Chain Structure of Ustekinumab
Figure 85. Channels of Distribution
Figure 86. Global Ustekinumab Sales Market Forecast by Region (2024-2029)
Figure 87. Global Ustekinumab Revenue Market Share Forecast by Region (2024-2029)
Figure 88. Global Ustekinumab Sales Market Share Forecast by Type (2024-2029)
Figure 89. Global Ustekinumab Revenue Market Share Forecast by Type (2024-2029)
Figure 90. Global Ustekinumab Sales Market Share Forecast by Application (2024-2029)
Figure 91. Global Ustekinumab Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Ustekinumab
Figure 2. Ustekinumab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ustekinumab Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Ustekinumab Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Ustekinumab Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Intravenous
Figure 10. Product Picture of Subcutaneous
Figure 11. Global Ustekinumab Sales Market Share by Type in 2022
Figure 12. Global Ustekinumab Revenue Market Share by Type (2018-2023)
Figure 13. Ustekinumab Consumed in Arthritis
Figure 14. Global Ustekinumab Market: Arthritis (2018-2023) & (K Units)
Figure 15. Ustekinumab Consumed in Colitis
Figure 16. Global Ustekinumab Market: Colitis (2018-2023) & (K Units)
Figure 17. Ustekinumab Consumed in Lupus Erythematosus
Figure 18. Global Ustekinumab Market: Lupus Erythematosus (2018-2023) & (K Units)
Figure 19. Ustekinumab Consumed in Myositis Multiplex With Palmoplantar Pustulosis
Figure 20. Global Ustekinumab Market: Myositis Multiplex With Palmoplantar Pustulosis (2018-2023) & (K Units)
Figure 21. Ustekinumab Consumed in Cirrhosis Of The Liver
Figure 22. Global Ustekinumab Market: Cirrhosis Of The Liver (2018-2023) & (K Units)
Figure 23. Ustekinumab Consumed in Sarcoidosis
Figure 24. Global Ustekinumab Market: Sarcoidosis (2018-2023) & (K Units)
Figure 25. Ustekinumab Consumed in Diabetes
Figure 26. Global Ustekinumab Market: Diabetes (2018-2023) & (K Units)
Figure 27. Ustekinumab Consumed in Other
Figure 28. Global Ustekinumab Market: Other (2018-2023) & (K Units)
Figure 29. Global Ustekinumab Sales Market Share by Application (2022)
Figure 30. Global Ustekinumab Revenue Market Share by Application in 2022
Figure 31. Ustekinumab Sales Market by Company in 2022 (K Units)
Figure 32. Global Ustekinumab Sales Market Share by Company in 2022
Figure 33. Ustekinumab Revenue Market by Company in 2022 ($ Million)
Figure 34. Global Ustekinumab Revenue Market Share by Company in 2022
Figure 35. Global Ustekinumab Sales Market Share by Geographic Region (2018-2023)
Figure 36. Global Ustekinumab Revenue Market Share by Geographic Region in 2022
Figure 37. Americas Ustekinumab Sales 2018-2023 (K Units)
Figure 38. Americas Ustekinumab Revenue 2018-2023 ($ Millions)
Figure 39. APAC Ustekinumab Sales 2018-2023 (K Units)
Figure 40. APAC Ustekinumab Revenue 2018-2023 ($ Millions)
Figure 41. Europe Ustekinumab Sales 2018-2023 (K Units)
Figure 42. Europe Ustekinumab Revenue 2018-2023 ($ Millions)
Figure 43. Middle East & Africa Ustekinumab Sales 2018-2023 (K Units)
Figure 44. Middle East & Africa Ustekinumab Revenue 2018-2023 ($ Millions)
Figure 45. Americas Ustekinumab Sales Market Share by Country in 2022
Figure 46. Americas Ustekinumab Revenue Market Share by Country in 2022
Figure 47. Americas Ustekinumab Sales Market Share by Type (2018-2023)
Figure 48. Americas Ustekinumab Sales Market Share by Application (2018-2023)
Figure 49. United States Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 50. Canada Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 51. Mexico Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 52. Brazil Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 53. APAC Ustekinumab Sales Market Share by Region in 2022
Figure 54. APAC Ustekinumab Revenue Market Share by Regions in 2022
Figure 55. APAC Ustekinumab Sales Market Share by Type (2018-2023)
Figure 56. APAC Ustekinumab Sales Market Share by Application (2018-2023)
Figure 57. China Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 58. Japan Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 59. South Korea Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 60. Southeast Asia Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 61. India Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 62. Australia Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 63. China Taiwan Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 64. Europe Ustekinumab Sales Market Share by Country in 2022
Figure 65. Europe Ustekinumab Revenue Market Share by Country in 2022
Figure 66. Europe Ustekinumab Sales Market Share by Type (2018-2023)
Figure 67. Europe Ustekinumab Sales Market Share by Application (2018-2023)
Figure 68. Germany Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 69. France Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 70. UK Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 71. Italy Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 72. Russia Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 73. Middle East & Africa Ustekinumab Sales Market Share by Country in 2022
Figure 74. Middle East & Africa Ustekinumab Revenue Market Share by Country in 2022
Figure 75. Middle East & Africa Ustekinumab Sales Market Share by Type (2018-2023)
Figure 76. Middle East & Africa Ustekinumab Sales Market Share by Application (2018-2023)
Figure 77. Egypt Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 78. South Africa Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 79. Israel Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 80. Turkey Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 81. GCC Country Ustekinumab Revenue Growth 2018-2023 ($ Millions)
Figure 82. Manufacturing Cost Structure Analysis of Ustekinumab in 2022
Figure 83. Manufacturing Process Analysis of Ustekinumab
Figure 84. Industry Chain Structure of Ustekinumab
Figure 85. Channels of Distribution
Figure 86. Global Ustekinumab Sales Market Forecast by Region (2024-2029)
Figure 87. Global Ustekinumab Revenue Market Share Forecast by Region (2024-2029)
Figure 88. Global Ustekinumab Sales Market Share Forecast by Type (2024-2029)
Figure 89. Global Ustekinumab Revenue Market Share Forecast by Type (2024-2029)
Figure 90. Global Ustekinumab Sales Market Share Forecast by Application (2024-2029)
Figure 91. Global Ustekinumab Revenue Market Share Forecast by Application (2024-2029)
